DUBLIN, Oct. 16, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that new data from its gastroenterology portfolio will be featured at the World Congress of Gastroenterology (WCOG), American College of Gastroenterology (ACG), from October 13–18, 2017 in Orlando, Florida.
"Through our innovation and Open Science research and development model, our dedication to collaborations allows Allergan to continue to be on the cutting-edge in the field of gastroenterology," said David Nicholson, Ph.D., Chief Research and Development Officer, Allergan. "Our presentations at WCOG cover our two effective treatment options for Irritable Bowel Syndrome with Diarrhea (IBS-D), Irritable Bowel Syndrome with Constipation (IBS-C), and Chronic Idiopathic Constipation (CIC).We are excited to share these results with the gastroenterology community and continue to work with them to realize the full potential of our medicines."
A key presentation will include the radar plots used to display disparate global effects of eluxadoline in a large group of patients who typically experience a broad range of symptoms associated with Irritable Bowel Syndrome with Diarrhea (IBS-D) (Poster #P2029).
Three abstracts will also be presented about linaclotide:
About VIBERZI® (Eluxadoline)
Eluxadoline is marketed by Allergan in the United States as VIBERZI® (eluxadoline) CIV. VIBERZI® is a twice daily, oral medication used to treat adults with irritable bowel syndrome with diarrhea (IBS-D). VIBERZI® has mixed opioid receptor modulator activity; it is a mu- and kappa-opioid receptor agonist and a delta-opioid receptor antagonist. VIBERZI® is thought to decrease visceral hypersensitivity and control GI motility, based on nonclinical studies. VIBERZI® is indicated for the treatment of IBS-D in adult men and women. Please also see full Prescribing Information: https://www.allergan.com/assets/pdf/viberzi_pi.
IMPORTANT SAFETY INFORMATION
Contraindications
VIBERZI is contraindicated in patients:
Warnings and Precautions
Pancreatitis:
Sphincter of Oddi Spasm:
Adverse Reactions
About LINZESS® (Linaclotide)
LINZESS® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Please see full Prescribing Information: http://www.allergan.com/assets/pdf/linzess_pi. Linaclotide is a guanylate cyclase‐C (GC‐C) agonist. Linaclotide binds to the GC-C receptor locally, within the intestinal epithelium, and is thought to work in two ways, based on nonclinical studies. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit, as well as a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established. Linaclotide is marketed by Allergan plc and Ironwood Pharmaceuticals in the United States as LINZESS®, with greater than 1.5 million unique patients in the United States having filled more than 8 million prescriptions since launch, per QuintilesIMS. In Europe, Allergan markets linaclotide under the brand name Constella® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood's partner Astellas markets linaclotide under the brand name LINZESS® for the treatment of adults with IBS-C. Ironwood also has partnered with AstraZeneca for development and commercialization of linaclotide in China, Hong Kong and Macau and with Allergan for development and commercialization of linaclotide in all other territories worldwide.
INDICATIONS AND USAGE
LINZESS (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
LINZESS is contraindicated in patients less than 6 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration. Use of LINZESS should be avoided in patients 6 years to less than 18 years of age. The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age.
Contraindications
Warnings and Precautions
Pediatric Risk:
Diarrhea:
Common Adverse Reactions (incidence ≥2% and greater than placebo)
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.
Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS: Allergan:
Investors:
Daphne Karydas
(862) 261-8006
Media:
Mark Marmur
(862) 261-7558
Tara Schuh
(201) 427-8888
SOURCE Allergan plc